SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES

• A Phase III clinical trial demonstrated that Xacrel, a biosimilar of ocrelizumab, is equivalent to Ocrevus in reducing the annualized relapse rate (ARR) in patients with relapsing-remitting multiple sclerosis (RRMS). • The study, conducted over 96 weeks, showed no significant difference in disability progression, relapse-free rates, or MRI lesion activity between patients treated with Xacrel and those treated with Ocrevus. • Safety profiles were comparable between the two groups, with similar incidences of adverse events, infusion reactions, and immunogenicity, supporting Xacrel as a potential cost-effective alternative to Ocrevus. • The findings suggest that Xacrel could expand access to B-cell-depleting therapy for MS patients, offering a more affordable treatment option without compromising efficacy or safety.

SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES

Ocrelizumab Biosimilar Xacrel Demonstrates Equivalent Efficacy and Safety in Multiple Sclerosis Trial